Charles G. Drake was presented with a unique opportunity to build a genitourinary cancer group with the focus on trying to cure these cancers with the immune system.

The promise of immunotherapy is altering how many cancers are perceived and treated, but it has so far eluded the treatment for some of the more aggressive malignancies, including ovarian cancer.